| Literature DB >> 32665174 |
Juan M Pericàs1, Andrea Arenas2, Orla Torrallardona-Murphy2, Helena Valero2, David Nicolás2.
Abstract
Entities:
Keywords: COVID-19; Editorial policies; Publishing trends; Scientific evidence; Scientific journals
Mesh:
Year: 2020 PMID: 32665174 PMCID: PMC7346840 DOI: 10.1016/j.ejim.2020.07.005
Source DB: PubMed Journal: Eur J Intern Med ISSN: 0953-6205 Impact factor: 4.487
Characteristics of articles on COVID-19 published in top-ranked journals during the study period.
| General features | |
|---|---|
| Articles published | |
| - Total | 32,249 |
| - Median per journal (IQR) | 141 (77–289.5) |
| COVID articles published | |
| - Total, n (%) | 2209 (6.8%) |
| - Median (IQR) | 4 (0–14.8) |
| - Impact factor, median (IQR) | 10.491 (7.167–16.601) |
| - Eigen factor, median (IQR | 0.04 (0.02–0.07) |
| - Associated to scientific society or institution, n (%) | 74 (46.3%) |
| - Specific COVID-19 section in webpage, n (%) | 63 (39.4%) |
| - Annual Rev Virology | 3/4 (75%) |
| - Eurosurveillance | 54/104 (51.9%) |
| - J infection | 107/241 (44.4%) |
| - Lancet Public Health | 32/89 (36%) |
| - Lancet Infectious Diseases | 93/310 (30%) |
| - Lancet | 175/653 (26.8%) |
| - Lancet Resp Med | 51/191 (26.7%) |
| - Nature Rev Immunol | 25/101 (24.8%) |
| By category. COVID-19 articles/total, n (%) | |
| - Medicine, general and internal | 621/4085 (15.2%) |
| - Infectious diseases | 421/2992 (14.1%) |
| - Public, environmental and occupational health | 98/779 (12.6%) |
| - Immunology | 145/1829 (7.9%) |
| - Respiratory system | 191/2757 (6.9%) |
| - Critical care medicine | 135/2433 (5.5%) |
| - Cardiac and cardiovascular surgery | 127/2338 (5.4%) |
| - Gastroenterology | 106/2466 (4.3%) |
| - Oncology | 55/1429 (3.8%) |
| - Surgery | 87/2424 (3.6%) |
| - Radiology | 78/2142 (3.6%) |
| - Medicine, research and experimental | 48/1381 (3.5%) |
| - Virology | 37/1208 (3.1%) |
| - Microbiology | 10/568 (1.8%) |
| - Haematology | 31/1852 (1.7%) |
| - Clinical neurology | 19/1566 (1.2%) |
| Multinational studies, n (%) | 333 (15.1%) |
| Country of corresponding author | |
| - United States | 752 (34%) |
| - China | 544 (24.6%) |
| - United Kingdom | 273 (12.4%) |
| - Italy | 170 (7.7%) |
| - France | 59 (2.7%) |
| - Singapore | 58 (2.6%) |
| - Canada | 43 (1.9%) |
| - Switzerland | 40 (1.8%) |
| - Germany | 32 (1.4%) |
| - Netherlands | 30 (1.4%) |
| - Other | 208 (9.4%) |
| Total number of countries | 56 |
| Original articles | 465 (21%) |
| - Randomized clinical trials | 2 (0.4%) |
| - Mathematical models | 9 (1.9%) |
| Reviews | 102 (4.6%) |
| Commentary* | 1537 (69.6%) |
| Case reports | 105 (4.8%) |
| Epidemiology | 329 (14.9%) |
| Interventions and health services | 475 (21.5%) |
| Clinical manifestations and prognosis | 502 (22.7%) |
| Microbiology | 75 (3.4%) |
| Diagnosis | 182 (8.2%) |
| Management | 205 (9.3%) |
| Immunology | 47 (2.1%) |
| Other | 394 (17.8%) |
| Health inequalities | 78 (3.5%) |
| Drug interactions | 26 (1.2%) |
*Including pieces such as Editorials. Correspondence/Letters to Editor. Perspectives. Comments. and Overview.
Fig. 1COVID-19 publishing timeline during the study period.